First-quarter sales for Boston Scientific Corp. slipped 1.8 percent to $2.01 billion, compared with $2.05 billion during the same period last year, as it struggles with a large chunk of long-term debt and fights expensive legal battles on a number of fronts.
The Natick-based devices giant plunged into the red, posting a $13 million net loss for the quarter ending March 31, compared with net income of $322 million during the first quarter of 2008.
The Boston-based company’s device is designed to be inserted into the hearts of patients with defects in the wall between the ventricular chambers.
The StarFlex implant closes the defect, preventing already-oxygenated blood from returning to the lungs before being pumped back into the body.
You’d think after about 20 years, questions about the efficacy of stents would be settled. You’d be wrong.
Analysis of data from the study, which aims to determine whether the device can help prevent stroke or ischemia from patent formane ovale, is due to be released during the fourth quarter of 2010. PFO is a defect in the septum separating the heart’s atrial chambers.
The StarFlex implant closes the defect, preventing venous blood from returning to the body without being oxygenated by the lungs.
The outcome of the 10-year court battle is still murky, despite the ruling, which failed to determine “the question of who owes what to whom,” according to the journal.
A three-year trial comparing Abbott Laboratories‘ Xience V drug-eluting stent against its Taxus competitor from Boston Scientific Corp. showed that the Abbott device is much more effective three years after implantation.
The news, announced at an American College of Cardiology conference in Orlando, sent the Natick device goliath’s stock into a slight swoon. The Xience product is already outselling the Taxus, and the news promises to accelerate that trend.
March 16 capped off a rough week for Boston Scientific Corp. and its Taxus stent line.
Two days later, the same day the Natick-based device giant settled a patent infringement case filed by a Texas physician, it was slapped with another by a Hong Kong cardiovascular device maker.